Semaglutide treatment of hypothalamic obesity – a real-life data study
Authors' conclusion
Treatment with semaglutide shows promising results in reducing body weight in patients with acquired hypothalamic obesity. Whether the weight reduction remains stable after long time follow-up needs further investigation.
Study context
- Population
- Patients with hypothalamic obesity due to tumors involving the hypothalamic region, outpatient clinic, Department of Endocrinology, Rigshospitalet, September 2020 to November 2023; 15 females, median age 52 (range 18–65) years; Body mass index (BMI) at semaglutide initiation median 38 (range 28–58) kg/m²15 females
- Participants
- 26 patients
- Exposure
- Before vs after semaglutide treatment
- Semaglutiden = 26
- Outcome
- Weight change before and after semaglutide treatment
- Follow-up
- 12 months
Methodological detailssingle-centre, real-life data
- Single-centre
- Real-life data
Main finding
As reported in the abstract
Weight loss
Semaglutide
13.4
mean · 95% CI 10.3–16.5 · kg
- Mean weight loss, p
- P = < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Loss in BMI · 12 months | Semaglutide 4.4 (95% CI 3.4–5.4) kg/m² |
| Lost >10% of initial body weight | Semaglutide 58% |
| Lost >20% of initial body weight | Semaglutide 8% |
- Loss in BMI — BMI loss, p
- p = < 0.001
Original publication
Semaglutide treatment of hypothalamic obesity – a real-life data study. Pituitary. Published 9 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →